Dual-targeted therapies + chemo shows high response rates in BRAF-mutated metastatic CRC, phase III trial shows

CRUK and partners pledge £5.5m funding for colorectal cancer research

Cancer Research UK and partners on March 31 committed £5.5 million in funding to form a research team tasked with making personalized medicine a reality for people with colorectal cancer. The initiative is designed to unite research expertise and solve unanswered questions about the disease.

April 04, 2025

Vol.51 No.13

Drugs & Targets

Exact Sciences launches the Cologuard Plus test for colorectal cancer screening

Exact Sciences Corp. announced the launch of Cologuard Plus, the most accurate noninvasive colorectal cancer screening test reported in studies to date. FDA-approved for average-risk patients 45+ and covered by Medicare, the Cologuard Plus test detects 95% of colorectal cancers at 94% specificity in the U.S. screening population.

April 04, 2025

Vol.51 No.13

In Brief

Karen Knudsen joins Paradigm Health’s board of directors as company prepares launch of AI-driven clinical trial data collection and management application

Paradigm Health announced on March 20 the appointment of Karen E. Knudsen to its board of directors, alongside the upcoming launch of its eSource clinical trial data application.

March 28, 2025

Vol.51 No.12

Clinical Roundup

Pandemic caused temporary disruptions in CRC screening and minimal impact on diagnosis, two studies show

Two recent studies by researchers from Regenstrief Institute and the Indiana University School of Medicine explore the effect of the pandemic on colorectal cancer screening tests and diagnostic colonoscopies in central Indiana.

March 28, 2025

Vol.51 No.12

Clinical Roundup

Investigational Orca-T treatment for hematologic malignancies meets primary endpoint in phase III trial

Orca Bio, a late-stage biotechnology company, on March 17 announced results from the pivotal phase III Precision-T study of Orca-T, its lead investigational allogeneic T-cell immunotherapy, in patients with acute myeloid leukemia, acute lymphoblastic leukemia, high-risk myelodysplastic syndrome and mixed-phenotype acute leukemia. Orca-T is manufactured using highly purified regulatory T-cells, hematopoietic stem cells and conventional T-cells derived from peripheral blood from either related or unrelated matched donors.

March 28, 2025

Vol.51 No.12

News Analysis

Trump’s tariffs will likely affect cancer drugs and devices—and may deepen drug shortages

For over a month since President Trump announced his intent to impose aggressive new tariffs on America’s friends and foes alike, lobbyists for hospitals, medical societies, and makers of branded and generic drugs have been trying to convince him to rethink.

March 21, 2025

Vol.51 No.11

By Claire Marie Porter and Jacquelyn Cobb

Dual-targeted therapies + chemo shows high response rates in BRAF-mutated metastatic CRC, phase III trial shows

YOU MAY BE INTERESTED IN

CRUK and partners pledge £5.5m funding for colorectal cancer research

Exact Sciences launches the Cologuard Plus test for colorectal cancer screening

Karen Knudsen joins Paradigm Health’s board of directors as company prepares launch of AI-driven clinical trial data collection and management application

Pandemic caused temporary disruptions in CRC screening and minimal impact on diagnosis, two studies show

Investigational Orca-T treatment for hematologic malignancies meets primary endpoint in phase III trial

Trump’s tariffs will likely affect cancer drugs and devices—and may deepen drug shortages

Renew today!

Subscriber content